Modulation Effects of Baduanjin Exercise on Subjective Cognitive Decline
NCT ID: NCT04009382
Last Updated: 2025-06-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
124 participants
INTERVENTIONAL
2020-08-31
2025-02-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Body and Brain Exercise for Older Adults With Memory Complaints
NCT02136368
Neurophysiological Effects of Mind-body Exercise in Healthy Adults
NCT06337344
Intervention Effect of Yizhi Baduanjin on Patients With Mild Cognitive Impairment
NCT05899777
Effectiveness Of Computer-Based Cognitive Training in Age-Related Cognitive Decline
NCT06226103
Effects Multimodal Mind and Body Approach for MCI
NCT06814483
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Recently, mind-body interventions have demonstrated their potential in preventing cognitive decline. Nevertheless, these mind-body therapies encompass a family of complex practices, each with different characteristics and focus. Therefore, they may be associated with different mechanisms and treatment effects. Baduanjin (BDJ) is an innovative and simple mind-body exercise consisting of eight simple movements that can be easily practiced at home with video guidance, thereby making it a more suitable option for older adults with cognitive decline than other more complex exercises.
We believe that this study will 1) significantly improve the prevention of MCI and AD and directly benefit patients suffering from these highly prevalent disorders, 2) enhance the investigators' understandings of the neurobiology through which mind-body interventions affect cognition and health, and 3) advance the investigators' understandings of the pathophysiology and development of SCD, AD, and age-related dementia.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Baduanjin
This group will participate in the Baduanjin exercise intervention for 24 weeks (three times/week for the first three months and two times/week for the last three months).
Baduanjin Exercise
Subjects will participate in Baduanjin, a simple mind-body exercise, for 24 weeks.
Cognitive Fitness Program
This group will participate in the Cognitive Fitness Program intervention for 24 weeks (three times/week for the first three months and two times/week for the last three months).
Cognitive Fitness Program
Subjects will complete paper puzzles (Sudoku, crosswords, etc.) for 24 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Baduanjin Exercise
Subjects will participate in Baduanjin, a simple mind-body exercise, for 24 weeks.
Cognitive Fitness Program
Subjects will complete paper puzzles (Sudoku, crosswords, etc.) for 24 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Self-reported experience of persistent decline in memory compared with a previous state (within the past 5 years), which was further confirmed by informants
* Concerns regarding memory problems
* Mini-Mental State Examination, Second Edition (MMSE-2) scores within the normal range
* Montreal Cognitive Assessment scores within the normal range (adjusted for age, sex, and education)
* Clinical Dementia Rating score of 0 (no memory loss or slight, inconsistent forgetfulness)
Exclusion Criteria
* Diagnosis of depression
* Other diseases that cause cognitive decline (e.g., traumatic brain injury, stroke, neurodegenerative diseases, brain tumor, Parkinson disease, encephalitis or epilepsy, thyroid dysfunction, severe anemia, syphilis)
* History of psychosis or congenital mental growth retardation
* Any delayed recall index greater than 1.5 SD below average on the California Verbal Learning Test, Second Edition
* Failing the Memory items on the MMSE-2 and MDRS-2, as well as the CVLT-II criterion
* Inability to participate in a 6-month intervention with a 3-month follow-up
* Any item = 0 on the Lawton-Brody Instrumental Activities of Daily Living Scale for cognitive reasons
* No available informant
* Previous diagnosis of MCI, AD, or other age-related dementia
* Previous Baduanjin experience
50 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jian Kong
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Massachusetts General Hospital
Charlestown, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018P001997
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.